Redx Pharma (REDX.L)

Executive Summary

Redx Pharma is a UK-based clinical-stage biotechnology company specializing in the discovery and development of novel small molecule therapies for fibrotic diseases and cancer. The company leverages its medicinal chemistry expertise to build a pipeline of targeted candidates, with lead programs including RXC007, a ROCK2 inhibitor in Phase 2 for idiopathic pulmonary fibrosis (IPF), and RXC004, a DDR1 inhibitor advancing for fibrotic indications. Redx also has an oncology portfolio with partnered programs, such as the BTK inhibitor licensed to Jazz Pharmaceuticals. Founded in 2010 and listed on AIM (REDX.L), the company has demonstrated clinical proof-of-concept and continues to progress its pipeline towards registration studies. In 2025, Redx reported positive interim Phase 2 data for RXC007 in IPF, showing favorable safety and efficacy trends. The company expects to release top-line results from this trial in the second half of 2026, which could be a major value inflection point. Additionally, Redx is anticipating the start of a Phase 2 trial for RXC004 in fibrotic diseases, and may pursue strategic partnerships to maximize the value of its oncology assets. With a strong cash position and a focused strategy, Redx is well-positioned to deliver on key milestones that could drive significant shareholder value.

Upcoming Catalysts (preview)

• H2 2026Phase 2 topline data for RXC007 in IPF40% success
• H1 2026Initiation of Phase 2 trial for RXC004 in fibrosis80% success
• 2026Potential partnership or licensing deal for oncology pipeline50% success